Marco Hofmann (@marcohhofmann) 's Twitter Profile
Marco Hofmann

@marcohhofmann

biologist, scientist, drug-hunter, oncology research

ID: 1189282415652548611

calendar_today29-10-2019 20:46:58

26 Tweet

150 Followers

141 Following

Marco Hofmann (@marcohhofmann) 's Twitter Profile Photo

Our SOS1::KRAS inhibitor BI-3406 manuscript got published Cancer Discovery:Combining SOS1::KRAS and MEK inhibition provides an attractive therapeutic concept for the majority of KRAS mutant cancers, including KRAS G12D, G12V, G12C and G13D Boehringer Ingelheim cancerdiscovery.aacrjournals.org/content/early/…

Boehringer Ingelheim (@boehringer) 's Twitter Profile Photo

#PRESS: We’re teaming up with @MiratiTx to investigate the combination of our SOS1::pan-KRAS inhibitor with their #KRAS G12C selective inhibitor ➡ bit.ly/2FG54IF

#PRESS: We’re teaming up with @MiratiTx to investigate the combination of our SOS1::pan-KRAS inhibitor with their #KRAS G12C selective inhibitor ➡ bit.ly/2FG54IF
Darryl B McConnell (@d_b_mcconnell) 's Twitter Profile Photo

Exciting news on Boehringer collaborating with Mirati on KRAS. Combining our SOS1 inhibitor with Mirati's KRAS-G12C in the clinic. boehringer-ingelheim.us/press-release/…

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now published & formatted in the January 2021 issue of Cancer Discovery Cancer Discovery - cancerdiscovery.aacrjournals.org/content/candis… Marco Hofmann Norbert Kraut Tim Heffernan Boehringer Ingelheim

Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now published &amp; formatted in the January 2021 issue of Cancer Discovery <a href="/CD_AACR/">Cancer Discovery</a> -  cancerdiscovery.aacrjournals.org/content/candis… <a href="/MarcoHHofmann/">Marco Hofmann</a> <a href="/norbertkraut1/">Norbert Kraut</a> <a href="/timheff5/">Tim Heffernan</a> <a href="/Boehringer/">Boehringer Ingelheim</a>
Dirk Kessler (@real_dr_kessler) 's Twitter Profile Photo

So exited to share our latest paper on SOS1 and the Discovery of BI-3406. Switching from a fluorine to a chlorine makes an inhibitor out of an activator. One Atom Makes All the Difference! Darryl B McConnell ACS Publications Bio & Med Chem Content pubs.acs.org/doi/10.1021/ac…

Vivek Subbiah, MD (@viveksubbiah) 's Twitter Profile Photo

🚨⭐️MD Anderson & Boehringer Ingelheim have expanded their joint Virtual Research & Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer Tim Heffernan #AACR21 MD Anderson Cancer Center Boehringer Ingelheim app.bronto.com/public/?q=prev…

🚨⭐️MD Anderson &amp; Boehringer Ingelheim have expanded their joint Virtual Research &amp;  Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer <a href="/timheff5/">Tim Heffernan</a> #AACR21 
<a href="/MDAndersonNews/">MD Anderson Cancer Center</a> <a href="/boehringerus/">Boehringer Ingelheim</a> 
app.bronto.com/public/?q=prev…
Norbert Kraut (@norbertkraut1) 's Twitter Profile Photo

Excited to partner with Amgen, combining our clinical-stage SOS1::pan-KRAS inhibitor with sotorasib, the first US FDA approved KRAS-G12C inhibitor. #KRAS #first4patients

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

📢Expanding the reach of precision🎯oncology by drugging all #KRAS mutants - our new review is out in Cancer Discovery dx.doi.org/10.1158/2159-8…. Thanks to Marco Hofmann, Daniel Gerlach, Sandra Misale, Mark, and Norbert Kraut #First4Patients #TakingCancerOn

📢Expanding the reach of precision🎯oncology by drugging all #KRAS mutants - our new review is out in 
<a href="/CD_AACR/">Cancer Discovery</a> dx.doi.org/10.1158/2159-8…. Thanks to <a href="/MarcoHHofmann/">Marco Hofmann</a>, <a href="/gerlach_d/">Daniel Gerlach</a>, <a href="/Sandra_Misale/">Sandra Misale</a>, Mark, and <a href="/norbertkraut1/">Norbert Kraut</a> #First4Patients #TakingCancerOn
Boehringer Ingelheim (@boehringer) 's Twitter Profile Photo

#RESEARCHERS: Our scientists foresee a concept of two potential future classes of #KRAS medicines - just published in Cancer Discovery! 👉 bit.ly/3nL3acD

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

🗓️Virtual conference upcoming "EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway" with a great line-up of speakers. Join on February 21-22, 2023 to get the latest updates in the field. Registration: eacr.org/conference/boe… EACR Boehringer Ingelheim

🗓️Virtual conference upcoming "EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway" with a great line-up of speakers. Join on February 21-22, 2023 to get the latest updates in the field. Registration: eacr.org/conference/boe… <a href="/EACRnews/">EACR</a> <a href="/Boehringer/">Boehringer Ingelheim</a>
Anirban Maitra (@aiims1742) 's Twitter Profile Photo

One of the best reviews this year on pharmacological targeting of KRAS - direct or indirect - is written by Norbert Kraut Sandra Misale Daniel Gerlach Marco Hofmann in Cancer Discovery - #OpenAccess & worth reading! aacrjournals.org/cancerdiscover…

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

Combined KRAS G12Ci + KRAS::SOS1i inhibition overcomes acquired resistance in Adagrasib-resistance CRC models - new pre-print from the Boehringer Ingelheim and MD Anderson Cancer Center partnership by venu☘️, Hengyu Lu and Marco Hofmann #KRAS #BI3406 #First4Patients doi.org/10.1101/2023.0…

Combined KRAS G12Ci + KRAS::SOS1i inhibition overcomes acquired resistance in Adagrasib-resistance CRC models - new pre-print from the <a href="/Boehringer/">Boehringer Ingelheim</a> and <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> partnership by <a href="/itsvenu_/">venu☘️</a>, Hengyu Lu and <a href="/MarcoHHofmann/">Marco Hofmann</a> #KRAS #BI3406 #First4Patients

doi.org/10.1101/2023.0…
venu☘️ (@itsvenu_) 's Twitter Profile Photo

Check out our work on KRAS G12Ci + KRAS::SOS1i as a viable combination therapy to address KRAS G12Ci resistance. This work is the result of Boehringer Ingelheim & MD Anderson Cancer Center partnership. #KRAS Daniel Gerlach Norbert Kraut Marco Hofmann KRASKickers biorxiv.org/content/10.110…

Anna Obenauf (@obenaufa) 's Twitter Profile Photo

Looking forward to an exciting program of the EACR Boehringer Ingelheim virtual conference "Drugging and Regulating the MAP Kinase Pathway" co-organized with #ReneBernards Marisol Soengas Marco Hofmann Ralph Neumüller So many developments in this field and challenges we need to tackle!

Looking forward to an exciting program of the   <a href="/EACRnews/">EACR</a>  <a href="/Boehringer/">Boehringer Ingelheim</a> virtual conference 
"Drugging and Regulating the MAP Kinase Pathway" co-organized with #ReneBernards <a href="/msmelanoma/">Marisol Soengas</a> <a href="/MarcoHHofmann/">Marco Hofmann</a> <a href="/Ralph_A_N/">Ralph Neumüller</a>
So many developments in this field and challenges we need to tackle!
Molecular Oncology (@moloncology) 's Twitter Profile Photo

The first session of #eacrMAPKpathway is underway with Marco Hofmann Boehringer Ingelheim introducing the interplay between inhibitors of SOS1 and KRAS Combination with SOS1i overcomes induced resistance to KRAS-G12Ci Does the upregulation of MRAS and RASGRP1 help explain resistance?

The first session of #eacrMAPKpathway is underway with <a href="/MarcoHHofmann/">Marco Hofmann</a> <a href="/Boehringer/">Boehringer Ingelheim</a> introducing the interplay between inhibitors of SOS1 and KRAS 

Combination with SOS1i overcomes induced resistance to KRAS-G12Ci 

Does the upregulation of MRAS and RASGRP1 help explain resistance?
Norbert Kraut (@norbertkraut1) 's Twitter Profile Photo

Out now in Nature Cancer. Our brand-new paper shows co-targeting of KRASG12C plus SOS1 as strategy for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors. Thanks to MD Anderson Cancer Center, Tim Heffernan and team and congrats to the Boehringer Ingelheim #KRAS team nature.com/articles/s4301…